share_log

D: Filing D

D: Filing D

D:發行公告
美股SEC公告 ·  10/15 22:05

牛牛AI助理已提取核心訊息

Aclarion, Inc., previously known as Nocimed, Inc., has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity offering with the first sale yet to occur as of September 30, 2024. The filing, signed by James Carroll as an Authorized Representative on October 15, 2024, states that the company is based in Broomfield, Colorado, and has been incorporated for over five years in Delaware. The offering is exempt under Rule 506(b) and has a total offering amount of $1,000,000 USD, with the entire amount already sold. The minimum investment accepted from any outside investor is set at $200,000 USD. Aclarion has not allocated any of the gross proceeds from the offering for payments to its executive...Show More
Aclarion, Inc., previously known as Nocimed, Inc., has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity offering with the first sale yet to occur as of September 30, 2024. The filing, signed by James Carroll as an Authorized Representative on October 15, 2024, states that the company is based in Broomfield, Colorado, and has been incorporated for over five years in Delaware. The offering is exempt under Rule 506(b) and has a total offering amount of $1,000,000 USD, with the entire amount already sold. The minimum investment accepted from any outside investor is set at $200,000 USD. Aclarion has not allocated any of the gross proceeds from the offering for payments to its executive officers, directors, or promoters. The company's executive officers and directors, including Brent Ness, Stephen Deitsch, David Neal, Scott Breidbart, Jeffrey Thramann, William Wesemann, Amanda Williams, and John Lorbiecki, are listed in the filing. The issuer has claimed that the offering will not last more than one year and is not being made in connection with a business combination transaction.
Aclarion,Inc.,前身爲Nocimed,Inc.,已向SEC提交了一份豁免發行證券的D表格通知,顯示一份新的權益發行通知將於2024年9月30日前尚未發生首次銷售。該申報文件由授權代表詹姆斯·卡羅爾在2024年10月15日簽署,說明公司總部位於科羅拉多州布魯姆菲爾德,並在特拉華州註冊成立已超過五年。該發行在506(b)規則下豁免,總髮行金額爲100萬美元,整個金額已全部出售。公司接受任何外部投資者的最低投資額設定爲20萬美元。Aclarion未將發行的總收入中的任何部分用於支付其高管、董事或推動者。公司的高管和董事,包括布倫特·內斯、史蒂芬·代奇、大衛·尼爾、斯科特·佈雷德巴特、傑夫裏·特拉曼、威廉·韋斯曼、阿曼達·威廉姆斯和約翰·洛比克,都列在申報文件中。發行人聲稱,該發行將不會超過一年,並且不是與業務合併交易有關。
Aclarion,Inc.,前身爲Nocimed,Inc.,已向SEC提交了一份豁免發行證券的D表格通知,顯示一份新的權益發行通知將於2024年9月30日前尚未發生首次銷售。該申報文件由授權代表詹姆斯·卡羅爾在2024年10月15日簽署,說明公司總部位於科羅拉多州布魯姆菲爾德,並在特拉華州註冊成立已超過五年。該發行在506(b)規則下豁免,總髮行金額爲100萬美元,整個金額已全部出售。公司接受任何外部投資者的最低投資額設定爲20萬美元。Aclarion未將發行的總收入中的任何部分用於支付其高管、董事或推動者。公司的高管和董事,包括布倫特·內斯、史蒂芬·代奇、大衛·尼爾、斯科特·佈雷德巴特、傑夫裏·特拉曼、威廉·韋斯曼、阿曼達·威廉姆斯和約翰·洛比克,都列在申報文件中。發行人聲稱,該發行將不會超過一年,並且不是與業務合併交易有關。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。